Mesoblast acquires global CAR technology license to advance autoimmune cell therapies
Mesoblast (NASDAQ:MESO) has expanded its advanced therapy pipeline by acquiring an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform.







_1380288_640x360_2496440899996-640x360.webp&w=3840&q=75)

_1380280_640x360_2496441923652-640x360.webp&w=3840&q=75)
_1380276_640x360_2496441923648-640x360.webp&w=3840&q=75)
